Analysis The Expression Of CD30 To Predict The Outcome In Patients With Diffuse Large B-Cell Lymphoma

Objective To investigate the expression and the prognostic value of CD30 in patients with not otherwise specifleddiffuse large B-cell lymphoma(DLBCL,NOS).Methods All 226 patients diagnosed as de novo DLBCL with the available CD30 expression statusin Fujian Medical University Union Hospital between January, 2007 and December, 2013 were confirmed according to WHO classification.We collected follow up data, record every patient's age, gender, ECOGscore, Ann Arbor state, international prognostic index(IPI) or age-adjusted IPI(a IPI),with or without B symptom, LDH, treatments, progression-free survival(PFS) and overall survival(OS). In statistical analysis, the Chi-squared test was applied to detect difference between those with and without CD30 expression and the method of Kaplan-Meier was used for survival analysis. The Log-rank test was used for survival curve test, and the COX's proportional hazards regression model was used for multiple prognostic factor analysis. All statistical significant were on the basis of 0.05. Calculations were performed by SPSS version 19.0 for Windows.Results Among all the 226 patients, the expression of CD30 was observed in 43 cases(19.00%). Most of the DLBCL patients with CD30 expression is younger person(age <60 year)(p=0.004). The DLBCL patients with CD30 expression showed less likely to present B symptoms(p=0.013) and more likely to present high LDH degree(p=0.026). There is no evidences show the relation of the CD30 with GCB or Non-GCB,Bcl-2,BCL-6,CD5 and Ki67(p=0.354, 0.898, 0.965, 0.992, 0.205).Patients with CD30 expression showed no significantly overall and event-freesurvivalcompared with CD30 negative patients(OS 75.70% VS 66.70%,p=0.319;PFS 45.70% VS 37.20%,p=0.353);the prognostic value of CD30 expression superior in DLBCLpatients treated with R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone), especially those with the low/low intermediate-risk IPI(p=0.048).The multivariate analysisrevealed that the expression of CD30 remained an favorable factor for both overall and event-free survival(p = 0.033 and 0.024).Conclusion These data suggest that CD30 is expressed predominantly in younger person. The expression of CD30 implied superior outcomein DLBCLpatientstreated with R-CHOP, especially those with the low/low intermediate-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be ofclinical interest.